MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology

MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology

Abstract Objective Tau hyperphosphorylation at threonine 217 (pT217) in cerebrospinal fluid (CSF) has recently been linked to early amyloidosis and could serve as a highly sensitive biomarker for Alzheimer’s disease (AD). However, it remains unclear whether other tauopathies induce pT217 modificatio...

Full description

Bibliographic Details
Main Authors: Chihiro Sato, Nipun Mallipeddi, Nupur Ghoshal, Brenton A. Wright, Gregory S. Day, Albert A. Davis, Albert H. Kim, Gregory J. Zipfel, Randall J. Bateman, Audrey Gabelle, Nicolas R. Barthélemy
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:Annals of Clinical and Translational Neurology
Subjects:
Alzheimer's Disease
Tauopathies
tau phosphorylation
mass spectrometry
cerebrospinal fluid
biomarker
Online Access:https://doi.org/10.1002/acn3.51435

Internet

https://doi.org/10.1002/acn3.51435

Similar Items